Evidence map›Paper›PMID 34510332›Full record

ReviewGeneral thoracic and cardiovascular surgery2022

Modifying strategies for SDF-1/CXCR4 interaction during mesenchymal stem cell transplantation.

Qin Jiang, Keli Huang, Fang Lu, Shaoping Deng, Zhenglin Yang, Shengshou Hu

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in General thoracic and cardiovascular surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Stem Cell Therapy against Ischemic Heart Disease.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. KnockdownBiomedicines · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qin Jiang *Department of Cardiac Surgery, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology, Chengdu, China.ORCID http://orcid.org/0000-0002-5821-359X
Keli Huang *Department of Cardiac Surgery, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology, Chengdu, China.
Fang Lu *Medico-Engineering Cooperation On Applied Medicine Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Shaoping DengDepartment for Organ Transplantation, Sichuan Academy of Medical Science, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Zhenglin YangThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No. 32, West Second Section First Ring Road, Chengdu, 610072, Sichuan, China. jq349@163.com.
Shengshou HuDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
University of Electronic Science and Technology of China · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CN

Funding

clinical translation research grant of sichuan provincial people's hospital 2017LY07National Natural Science and Technology Foundation of China 81800274sichuan science and technology program 2021JDJQ0041
6 · The paper itself

Abstract

Mesenchymal stem cell (MSC) transplantation is regarded as a promising candidate for the treatment of ischaemic heart disease. The major hurdles for successful clinical translation of MSC therapy are poor survival, retention, and engraftment in the infarcted heart. Stromal cell-derived factor-1/chemokine receptor 4 (SDF-1/CXCR4) constitutes one of the most efficient chemokine/chemokine receptor pairs regarding cell homing. In this review, we mainly focused on previous studies on how to regulate the SDF-1/CXCR4 interaction through various priming strategies to maximize the efficacy of mesenchymal stem cell transplantation on ischaemic hearts or to facilitate the required effects. The strengthened measures for enhancing the therapeutic efficacy of the SDF-1/CXCR4 interaction for mesenchymal stem cell transplantation included the combination of chemokines and cytokines, hormones and drugs, biomaterials, gene engineering, and hypoxia. The priming strategies on recipients for stem cell transplantation included ischaemic conditioning and device techniques.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMyocardial InfarctionMyocardial IschemiaChemokine CXCL12HumansReceptors, CXCR4Chemokine CXCL12CXCR4 protein, humanReceptors, CXCR4Cell transplantationCXCR4 receptorMesenchymal stem cellsMyocardial infarctionStromal cell-derived factor-1

Identifiers

PMID34510332
PMCPMC8732940
OpenAlexW3200896019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.